Jeffrey Cheung – General Partner & Co-Founder

Over 30 years of management experience, including 15 years of investing in promising early stage startups in Asia, Europe and the US;

Board member and advisor to startups on growth strategy and helped raise angel and series A funds to support their growth; Investment Committee member, Corporate Venture Fund of the HK Science and Technology Parks Corporation;

Successfully supported startups to company expansion, exits and IPO’s (iClick, OST etc.);

BSc from Penn M&T program (Engineering & Wharton), MSc from MIT Sloan and Executive Program from Stanford GSB;

Vincent Wong – General Partner & Co-Founder

Over 30 years of technology and consulting industry experience in the US, Europe and Asia;

Former Partner at PwC and VP/Senior Partner at IBM Global Services focusing on Digital and Business Model Innovation services in AsiaPac, Latin America, Japan, Middle East & Africa and Central Eastern Europe;

Incubated startup engines within IBM Global Services focusing on Cloud, AI, Blockchain, Big Data, IoT platforms;

BSc from Penn M&T program (Engineering & Wharton) and Executive MBA from the Wharton School of University of Pennsylvania; Bachelor of Laws from the University of London;

Mr. C. Scott Hartz

Chairman of TaaSera and CEO of the Hartz Group with over 40 years of strategy, technology consulting and senior leadership management experience;

Former Global CEO of PwC Consulting, consulting arm of PricewaterhouseCoopers, where Mr. Hartz led business growth from a revenue base of 900M to over 6.7B operating in 70 countries with 33,000 employees;

Current and former board member at Erie Indemnity Company, TaaSera, Averatek, Alien Technology, Satmetrix, Nexant and Siebel Systems; Previously member of the Wharton Graduate Executive Board and Lehigh University Business Advisory Board;

CPA, BSc from Lehigh University and MBA from the Wharton School of University of Pennsylvania;

Mr. Christopher M. Cashman

Board Chairman of MBF Therapeutics, Director of Noble Biomaterials, Rapid Micro Biosystems, Life Sciences Pennsylvania and University City Science Center;

Former chairman and CEO of Marinus Pharmaceuticals and Chairman of JDP Therapeutics; Former executive at SmithKline and Pfizer;

Over 40 years of experience as operating executive of early and mid stage biopharmaceutical companies and major divisions of big pharma;

BSc from University Minnesota and MSc from Purdue University;

Ms. Sharon Clarke

Chief Commercial Officer at Zensights with more than 20 years of senior leadership experience in healthcare;

Previously President and GM of Meda Pharmaceuticals and founder of Patriot Advisors providing consulting services to emerging biotechnology and established global pharmaceutical companies;

Member of the Board of Directors for JDP Therapeutics guiding the company to phase 3 clinical stage for small molecule therapeutics development;

B.A. from East Tennessee State University and Board of Trustees of the University Alumni Association from 2010 to 2017;

Dr. Bing Lou Wong

Vice Chairman of HK Biotechnology Organisation, CTO of New A Innovation Limited and Honorary Professor at the Department of Biochemistry of Chinese University of Hong Kong;

Over 40 years of experience in the development of protein therapeutics in Biotechnology Industry;

Previously Member of the Board of Director and CEO at Advantek Biologics Limited, Acting Director at the New England Enzyme Center and Associate Professor at Tufts Medical School of Boston;

Co-founded Biopure Corporation (NASDAQ : BPUR) in the US where Dr. Wong served as CTO and SVP;

Owner of a number of patents and has been a licensor to a number of world-leading companies such as Roche and Teva

Mr. Adam Butler

Former member of the management team of CRF Bracket (now Signant Health) from the company’s founding through its growth to one of the largest eClinical service providers;

Responsible for all of CRF Bracket’s commercial and strategic activities, leading the salesforce, marketing and communication efforts as well as investments in new product development and acquisitions;

Previous experience in Enterprise Software and Digital Asset Management software development for large and small firms, including HP, Apple and Fahrenheit 450;

Dr. Charles Hu

Medical Advisor at AstraZeneca and Co-Founder of Incando Therapeutics, a global medical device startup aimed at innovative treatments for cancer and neurodegenerative diseases;

Over 10 years of translational biomedical research and large-animal preclinical studies with a strong focus in tissue engineering and regenerative medicine, including biomedical devices, biomaterials design, drug/stem cell delivery, gene/cancer therapy, interventional radiology and biomedical imaging;

PhD from Johns Hopkins University (Tissue Engineering) and Institute for Nano-biotechnology (INBT) fellow; BSc from University of California, Berkeley (Bioengineering);

Mr. Joachim Osther

Founder and MD of Berea BioVentures, a life science consultancy providing strategic analysis supporting due diligence efforts, strategic business development, portfolio/market analysis, and partnership analysis;

Over 20 years of experience in life science industry including product launches at Eli Lilly and at Amylin Pharmaceuticals (acquired by Bristol Myers Squibb and Astra-Zeneca in 2012);

Former VP of Global Business Development for ElectroCore Inc, a medical device company and Board member of Dana Genetic, a European immuno-oncology start-up;

BA and AS/PTA from Washburn University;

Legal

Duane Morris LLP, founded in Philadelphia in 1904, is one of the top law firms in the world with more than 800 attorneys in offices across the United States and internationally, providing services to clients in industries ranging from healthcare/life sciences to venture capital and private equity firms.

Fund Administration, Finance and Accounting

Greenough Consulting Group (GCG) provides finance, accounting, and human resources services to Technology companies, Venture Capital and Private Equity Funds. Over two decades, GCG has served over 600 Technology companies and 200 Venture Capital and Alternative Investment Funds.